Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2024 Q1 | May 9, 2024 | Tourlite Capital Management | 4.5% | 13.8% | ABUS, APG, ESPR, FIP, FTAI, LGND, OABI, PRGO, PRPL, ROIV | Biotechnology, Hedging, Idiosyncratic, Long/Short, spinoffs, value | Fund maintains four biotech long positions representing ~20% of gross long exposure, viewed as idiosyncratic opportunities based on litigation or corporate events rather than binary drug results. Positions include Roivant Sciences with significant cash position and share buyback program, Arbutus benefiting from Covid vaccine litigation, OmniAb spinoff with 300+ drugs in pipeline, and a recent spinoff trading at 65% discount to cash. | PRGO ROIV ESPR PRPL APG FTAI FIP |
View |
| 2023 Q4 | Dec 29, 2023 | Clark Street Value | - | 38.5% | ACI, AVRO, BANC, CKX, CYT, ELYM, ESPR, FHN, FIXX, GRPH, HMST, KNTE, MBI, MRC, MREO, PIRS, RPHM, SAVE, SIOX, THRX | Biotechnology, M&A, real estate, Regional Banks, small caps, special situations, value | Manager holds a substantial broken biotech basket focused on companies undergoing strategic alternatives including reverse mergers, liquidations, and takeover offers. Multiple biotech positions are trading below net cash with potential value from IP assets and CVRs. | View | |
| 2023 Q3 | Oct 30, 2023 | Jacob Fund | - | - | ESPR, SOFI | Biotechnology, Fintech, growth, healthcare, small cap, technology | SoFi Technologies represents the evolution from student lending to comprehensive financial services platform. The company serves over 6 million customers with sophisticated risk pricing methods, offering competitive rates on loans and deposits to build long-term customer relationships. | ESPR SOFI |
View |
| 2023 Q4 | Jan 26, 2024 | Tourlite Capital Management | 4.5% | 13.8% | APG, ESPR, FC, FIP, FTAI, IMVT, KD, LTCH, PRM, PRVB, ROIV, SAN.PA | Aviation, Biotechnology, Event Driven, Long/Short, small caps, special situations | Fund initiated significant position in Roivant Sciences, a biotech company specializing in consolidating promising drug patents. Thesis based on cash value from asset sales, Immunovant stake, and pipeline upside potential. Also held Provention Bio which was acquired by Sanofi following FDA approval. | AFCG ROIV LTCH BKD FIP ESPR APG FTAI |
View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | Fund Letters | Tourlite Capital Management | Esperion Therapeutics | Health Care | Biotechnology | Neutral | NASDAQ | biotechnology, Cash runway, Catalyst, Event-driven, Litigation Settlement, Special Situation | View Pitch |
| Apr 28, 2026 | Fund Letters | Aristotle Atlantic Core Equity Strategy | Spirit AeroSystems Holdings, Inc. | Industrials | Aerospace & Defense | Bear | NYSE | 737 Max, 787, A220, A350, Aerospace, Airbus, Boeing, CEO change, manufacturing, Quality Issues | View Pitch |
| Apr 28, 2026 | Fund Letters | Jacob Fund | Esperion Therapeutics | Health Care | Biotechnology | Bull | NASDAQ | acquisition target, biotechnology, cardiovascular, Cholesterol, Clinical Outcomes, FDA-approved, Label Expansion, turnaround | View Pitch |
| Apr 13, 2026 | Fund Letters | Tourlite Capital Management | Esperion Therapeutics | Health Care | Biotechnology | Neutral | NASDAQ | biotechnology, Cash runway, Catalyst, Event-driven, litigation, settlement, Special situations | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||